27 Jun 2025
// PRESS RELEASE
27 Jun 2025
// PRESS RELEASE
16 Jun 2025
// PRESS RELEASE
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
About
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Booth # 9.1F6 & 9.1G41
28-30 October, 2025
Peptide Process CMCPeptide Process CMC
Industry Trade Show
Not Confirmed
28-30 August, 2025
Industry Trade Show
Not Confirmed
01-03 September, 2025
CONTACT DETAILS
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Booth # 9.1F6 & 9.1G41
28-30 October, 2025
Peptide Process CMCPeptide Process CMC
Industry Trade Show
Not Confirmed
28-30 August, 2025
Industry Trade Show
Not Confirmed
01-03 September, 2025
CORPORATE CONTENT #SupplierSpotlight
https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
27 Jun 2025
// PRESS RELEASE
https://strides.com/pdf/pressrelease/2025/SPSLTradingWindow_27_may_2025.pdf
27 Jun 2025
// PRESS RELEASE
https://strides.com/pdf/pressrelease/2025/Strides_Intimation_signed_27_may_2025.pdf
16 Jun 2025
// PRESS RELEASE
https://strides.com/pdf/pressrelease/2025/StridesSEIntimation_16Jun2025.pdf
30 May 2025
// PRESS RELEASE
https://strides.com/pdf/pressrelease/2025/Strides_Intimation_signed_30_may_2025.pdf
27 May 2025
// PRESS RELEASE
https://strides.com/pdf/pressrelease/2025/Strides_ASCR_FY25_signed_26_may_2025.pdf
23 May 2025
// PRESS RELEASE
https://strides.com/pdf/pressrelease/2025/SE_intimation_newspaper_Adv_signed_may_23_2025.pdf
Details:
The portfolio consists of liquids, including Nitrofurantoin, and immediate release solid orals to treat infections associated with UTIs, Pain Management, Allergy Symptoms, ADHD and Narcolepsy.
Lead Product(s): Nitrofurantoin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Nitrofurantoin-Generic
Study Phase: Approved FDFProduct Type: Antibiotic
Recipient: Nostrum Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition May 03, 2025
Lead Product(s) : Nitrofurantoin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Nostrum Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Strides Acquires Identified ANDAs from Nostrum Laboratories, USA
Details : The portfolio consists of liquids, including Nitrofurantoin, and immediate release solid orals to treat infections associated with UTIs, Pain Management, Allergy Symptoms, ADHD and Narcolepsy.
Product Name : Nitrofurantoin-Generic
Product Type : Antibiotic
Upfront Cash : Undisclosed
May 03, 2025
Details:
Celebrex-Generic (celecoxib) is a COX-2 inhibitor, small molecule drug candidate. It is indicated for the treatment of osteoarthritis & rheumatoid arthritis in adults.
Lead Product(s): Celecoxib,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Celebrex-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 30, 2025
Lead Product(s) : Celecoxib,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Pharma receives USFDA approval for Celecoxib Capsules in multiple strengths
Details : Celebrex-Generic (celecoxib) is a COX-2 inhibitor, small molecule drug candidate. It is indicated for the treatment of osteoarthritis & rheumatoid arthritis in adults.
Product Name : Celebrex-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 30, 2025
Details:
The company has received approval from the US Food and Drug Administration (USFDA) for generic version for Acetaminophen and Ibuprofen tablets (250 mg/125 mg) indicated for pain and inflammation.
Lead Product(s): Ibuprofen,Paracetamol
Therapeutic Area: Neurology Brand Name: Advil Dual Action
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 20, 2025
Lead Product(s) : Ibuprofen,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Gains USFDA Approval for Acetaminophen and Ibuprofen Tablets, 125 mg /250 mg
Details : The company has received approval from the US Food and Drug Administration (USFDA) for generic version for Acetaminophen and Ibuprofen tablets (250 mg/125 mg) indicated for pain and inflammation.
Product Name : Advil Dual Action
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2025
Details:
USFDA approved generic version of Sevelamer Carbonate which is used to manage elevated levels of phosphate in the blood of patients with chronic kidney disease.
Lead Product(s): Sevelamer Hydrochloride,Inapplicable
Therapeutic Area: Nephrology Brand Name: Renvela-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 05, 2024
Lead Product(s) : Sevelamer Hydrochloride,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Receives USFDA Approval for Sevelamer Carbonate Tablets
Details : USFDA approved generic version of Sevelamer Carbonate which is used to manage elevated levels of phosphate in the blood of patients with chronic kidney disease.
Product Name : Renvela-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 05, 2024
Details:
Fluoxetine hydrochloride, is an antidepressant of the SSRIs class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder, bulimia nervosa, etc.
Lead Product(s): Fluoxetine Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Prozac-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 18, 2024
Lead Product(s) : Fluoxetine Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Pharma Subsidiary Receives USFDA Approval for 60 mg Fluoxetine Tablets
Details : Fluoxetine hydrochloride, is an antidepressant of the SSRIs class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder, bulimia nervosa, etc.
Product Name : Prozac-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 18, 2024
Details:
Fluoxetine hydrochloride (Prozac) is an SSRI antidepressant used for major depressive disorder, OCD, bulimia, and panic disorder.
Lead Product(s): Fluoxetine Hydrochloride,Inapplicable
Therapeutic Area: Psychiatry/Psychology Brand Name: Prozac-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 04, 2024
Lead Product(s) : Fluoxetine Hydrochloride,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Pharma Gets USFDA Nod for Antidepressant Medication
Details : Fluoxetine hydrochloride (Prozac) is an SSRI antidepressant used for major depressive disorder, OCD, bulimia, and panic disorder.
Product Name : Prozac-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2024
Details:
Theophylline extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.
Lead Product(s): Theophylline,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Theo-Dur-Generic
Study Phase: Approved FDFProduct Type: Plant Extract/Herbal
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 09, 2024
Lead Product(s) : Theophylline,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Gets USFDA Nod for Theophylline Extended-Release Tablets
Details : Theophylline extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.
Product Name : Theo-Dur-Generic
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 09, 2024
Details:
Carafate-generic (sucralfate) is a USFDA approved pepsin A inhibitor small molecule drug candidate, which is indicated for the treatment of active duodenal ulcer.
Lead Product(s): SucrAlphate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Carafate-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2024
Lead Product(s) : SucrAlphate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL
Details : Carafate-generic (sucralfate) is a USFDA approved pepsin A inhibitor small molecule drug candidate, which is indicated for the treatment of active duodenal ulcer.
Product Name : Carafate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2024
Details:
USFDA approved generic version of Gabapentin tablet, which is an anticonvulsant medication primarily used to treat partial seizures and neuropathic pain.
Lead Product(s): Gabapentin,Inapplicable
Therapeutic Area: Neurology Brand Name: Neurontin-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 03, 2024
Lead Product(s) : Gabapentin,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Receives USFDA Approval for Gabapentin Tablets USP, 600 mg and 800 mg
Details : USFDA approved generic version of Gabapentin tablet, which is an anticonvulsant medication primarily used to treat partial seizures and neuropathic pain.
Product Name : Neurontin-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 03, 2024
Details:
USFDA approved generic version of Pregabalin treatment of fibromyalgia. It binds to the alpha2-delta subunit which is involved in anti-nociceptive and antiseizure effects.
Lead Product(s): Pregabalin,Inapplicable
Therapeutic Area: Musculoskeletal Brand Name: Lyrica-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 25, 2024
Lead Product(s) : Pregabalin,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Receives USFDA Approval for Pregabalin Capsules
Details : USFDA approved generic version of Pregabalin treatment of fibromyalgia. It binds to the alpha2-delta subunit which is involved in anti-nociceptive and antiseizure effects.
Product Name : Lyrica-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 25, 2024
Regulatory Info :
Registration Country : India
Dosage Form : Tablet
Brand Name : Abacavir
Dosage Strength : 300MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : RX
Registration Country : USA
Dosage Form : TABLET;ORAL
Brand Name : ACARBOSE
Dosage Strength : 25MG
Packaging :
Approval Date : 2011-07-27
Application Number : 90912
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Dosage Form : TABLET;ORAL
Brand Name : ACARBOSE
Dosage Strength : 100MG
Packaging :
Approval Date : 2011-07-27
Application Number : 90912
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : India
Dosage Form : Tablet
Brand Name : Acarbose
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : India
Dosage Form : Tablet
Brand Name : Acarbose
Dosage Strength : 25MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : RX
Registration Country : USA
Dosage Form : TABLET;ORAL
Brand Name : ACARBOSE
Dosage Strength : 50MG
Packaging :
Approval Date : 2011-07-27
Application Number : 90912
Regulatory Info : RX
Registration Country : USA
Regulatory Info :
Registration Country : India
Dosage Form : Tablet
Brand Name : Acarbose
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : RX
Registration Country : USA
ACETAMINOPHEN; BUTALBITAL; CAFFEINE
Dosage Form : TABLET;ORAL
Brand Name : BUTALBITAL, ACETAMINOPHEN...
Dosage Strength : 325MG;50MG;40MG
Packaging :
Approval Date : 2003-08-27
Application Number : 40511
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
ACETAMINOPHEN; BUTALBITAL; CAFFEINE
Dosage Form : TABLET;ORAL
Brand Name : BUTALBITAL, ACETAMINOPHEN...
Dosage Strength : 325MG;50MG;40MG
Packaging :
Approval Date : 2020-09-21
Application Number : 203647
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE
Dosage Form : CAPSULE;ORAL
Brand Name : BUTALBITAL, ACETAMINOPHEN...
Dosage Strength : 325MG;50MG;40MG;30MG
Packaging :
Approval Date : 2020-07-08
Application Number : 204649
Regulatory Info : RX
Registration Country : USA
Inspections and registrations
ABOUT THIS PAGE